Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2

Nazish, I; Mamais, A; Mallach, A; Bettencourt, C; Kaganovich, A; Warner, T; Hardy, J; Lewis, PA; Pocock, J; Cookson, MR; Bandopadhyay, R

doi:10.3390/cells13010053

All Outputs (2)

Multi-ancestry genome-wide association meta-analysis of Parkinson's disease (2023)
Journal Article
Kim, J., Vitale, D., Otani, D., Lian, M., Heilbron, K., Aslibekyan, S., …Mata, I. (2023). Multi-ancestry genome-wide association meta-analysis of Parkinson's disease. Nature Genetics, https://doi.org/10.1038/s41588-023-01584-8

Although over 90 independent risk variants have been identified for Parkinson's disease using genome-wide association studies, most studies have been performed in just one population at a time. Here we performed a large-scale multi-ancestry meta-anal... Read More about Multi-ancestry genome-wide association meta-analysis of Parkinson's disease.

Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2 (2023)
Journal Article
Nazish, I., Mamais, A., Mallach, A., Bettencourt, C., Kaganovich, A., Warner, T., …Bandopadhyay, R. (2023). Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2. Cells, 13(1), https://doi.org/10.3390/cells13010053

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause autosomal dominant Parkinson's disease (PD), with the most common causative mutation being the LRRK2 p.G2019S within the kinase domain. LRRK2 protein is highly expressed in the human br... Read More about Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2.